Home > Newsletters > Drug Industry Daily > EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs
Drug Industry Daily
Oct. 10, 2012 | Vol. 11 No. 199
EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs
Drugmakers evaluating multiple sclerosis (MS) treatments for the EU should use relapse rate as the primary efficacy parameter in clinical trials for relapsing-remitting MS or secondary progressive MS with superimposed relapses, according to a draft EMA guideline.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.